Biohaven rises after completing enrollment in mid-stage obesity drug trial

Biohaven

19/03/2026 12:42

** Shares of drugmaker Biohaven BHVN.N rise 2% to $9.26 premarket

** Co says it finished enrolling patients in a mid-stage trial for experimental obesity drug, taldefgrobep alfa,

** Expects trial results in second-half of 2026

** Says the injectable drug is being tested as a standalone treatment, given weekly or monthly, on overweight and obese adults

** Adds the study will track changes in weight, fat and muscle mass over 24 weeks, followed by a 24-week extension to see if changes to weight and body-composition sustain or improve over a longer period

** Earlier studies showed the experimental drug helped reduce fat, while preserving or increasing muscle with side effects similar to placebo

** Shares fell ~70% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))